SCHEMBL6288048

SCHEMBL6288048

N[C@](Cc1c[nH]c2ccccc12)(C(=O)Cc1ccsc1)C(=O)Nc1ccc(C(c2ccc(NC(=O)[C@@](N)(Cc3c[nH]c4ccccc34)C(=O)Cc3ccsc3)cc2)c2ccc(NC(=O)[C@@](N)(Cc3c[nH]c4ccccc34)C(=O)Cc3ccsc3)cc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.39
MAPT P10636 2/20 0.39
HTT P42858 2/20 0.39
PTBP1 P26599 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HRH3 Q9Y5N1 4/20 0.39
CCKBR P32239 1/20 0.38
MAPK8 P45983 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CYP1A2 P05177 1/20 0.38
POLB P06746 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
GOT1 P17174 2/20 0.37
ALDH1A1 P00352 2/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
ALOX12 P18054 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6287787 0.89 L3MBTL1 (0.44) LMNAMAPTHTTPTBP1SMN1; SMN2
SCHEMBL6290352 0.81 MAPT (0.41) LMNAMAPTHTTHRH3CCKBR
SCHEMBL6287689 0.81 L3MBTL1 (0.44) LMNAMAPTHTTPTBP1SMN1; SMN2
SCHEMBL6288045 0.79 MAPK8 (0.44) LMNAMAPTHTTPTBP1SMN1; SMN2
SCHEMBL6291029 0.78 RAB9A (0.43) MAPTSMN1; SMN2L3MBTL1POLBMEN1
SCHEMBL6288077 0.78 MAPK8 (0.42) LMNAMAPTHTTPTBP1SMN1; SMN2
SCHEMBL6288047 0.77 HDAC8 (0.54) LMNAMAPTHTTPTBP1SMN1; SMN2
SCHEMBL7037676 0.77 RAB9A (0.42) MAPTSMN1; SMN2L3MBTL1POLBKMT2A
Hydrochloric Acid SCHEMBL6286771 0.76 MC4R (0.43) MAPTHRH3MAPK8L3MBTL1ALDH1A1
Hydrochloric Acid SCHEMBL6290971 0.76 MC4R (0.43) MAPTHRH3MAPK8L3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6887890-B2 Compounds exhibiting thrombopoietin-like activities CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2005-05-03 US disclosed
US-20030162724-A1 Compounds exhibiting thrombopoietin-like activities CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-08-28 US disclosed
EP-1291341-A1 COMPOUNDS EXHIBITING THROMBOPOIETIN-LIKE ACTIVITIES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-03-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162724-A1 Compounds exhibiting thrombopoietin-like activities MPL, THPO, TEK LMNA 3699/4885MAPT 4866/4885HTT 3042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.